PLRX News and Press, Pliant Therapeutics Inc. From 11/06/25

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

2025-10-10 09:03:44 ET More on Allogene Therapeutics, Pliant Therapeutics Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript Allogene Therapeutics: Important Catalysts Guided For Early 2026 Allogene Therapeutics, Inc. (ALLO) Q2 202...

2025-08-07 17:52:25 ET More on Pliant Therapeutics Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast Seeking Alpha’s Quant Rating on Pliant Therapeutics Historical earnings data for Pliant Therapeutics Financial information for...

BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Ther...

Sera Prognostics Inc. (SERA) is expected to report $-0.21 for Q2 2025 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.51 for Q2 2025 Context Therapeutics Inc. (CNTX) is expected to report $-0.06 for Q2 2025 Genco Shipping & Trading ...

Pliant Therapeutics Inc. (PLRX) is expected to report $-0.62 for Q2 2025

2025-07-02 13:36:28 ET Our family office is experiencing one of its best years. It is mainly thanks to several stocks that I wrote about here on Seeking Alpha .... Read the full article on Seeking Alpha For further details see: From Nebius Group To EOS: A Strong Year And...

2025-06-27 16:32:50 ET More on Pliant Therapeutics Pliant Therapeutics: An Activist On Deck Pliant Therapeutics to trim about 45% of workforce Seeking Alpha’s Quant Rating on Pliant Therapeutics Historical earnings data for Pliant Therapeutics ...

Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) toda...

SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held f...